Myriad Genetics Reports Second Quarter Financial Results August 4, 2022 Highlights: Revenue of $179.3 million for the quarter ended June 30, 2022 Excluding revenue from divested businesses, revenue increased 7% year-over-year an... Continue Reading
Myriad Genetics to Release 2022 Second-Quarter Financial Results on Aug. 4, 2022 July 28, 2022 Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will hold its second-quarter earnings conference call on Thursday, Au... Continue Reading